KOTAI Biotechnology, Inc. and 3H Holdings Inc. utilize “Rare Disease Research and Development Program based on patient-centered principle” and call for patient participation in “Study of Specific Immune Conditions of Autoimmune Diseases”.
KOTAI Biotechnology, Inc. (Kazuo Yamashita, CEO, hereinafter referred to as “KOTAI”) and 3H Holdings Inc. (Sho Ando, CEO, formerly CROee, hereinafter referred to as “3H”) has released the information on “Study of Specific Immune Conditions of Autoimmune Diseases” conducted by KOTAI at the intractable disease and rare disease information site, “RareS.”, (https://raresnet.com/special/pcrd2-pro01/), in order to utilize “Patient Centricity in Rare Disease R&D Program, hereinafter referred to as “PCRD²” and call for of research cooperation among autoimmune disease patients. This is the first study of PCRD² jointly conducted by the University of Tokyo and 3H Holdings Inc.
Outline of research
Immune cells, T cells and B cells as target this time, are deeply involved in the onset and the progress of diseases in autoimmune diseases, while at the same time playing an important role in many diseases, such as cancer and infectious diseases. We will study the following two issues by analyzing the function of immune cell receptors called T-cell receptors and B-cell receptors), which play an important role as limbs of disease-related T cells and B cells:
- We will clarify the causes of “rare intractable autoimmune diseases” where the causes of the diseases are not clear and promote the creation of new therapeutic agents.
- We will explore the use of effective therapeutic agents for other diseases with regard to “rare intractable autoimmune diseases” that do not have therapeutic agents.
By conducting joint research with patients suffering from many “rare intractable autoimmune diseases”, we will continue to contribute to the creation of new drugs by obtaining research results that can be useful to many patients.
Target diseases
Those who are suffering from the disease and are currently undergoing treatment
Target diseases: Behcet’s disease, Ankylosing Spondylitis, Psoriasis, Polymyositis, Dermatomyositis, Adult Still’s Disease, Rapidly Progressive Glomerulonephritis
As of August 9, 2019, additional plans will be made in the future
For more information, please check the reception page.
Benefits to patients
After the analysis is completed, we will make a briefing the patients, who wish to have information, about the rough profiles of similarities and differences of each patient’s immunity in the study as a summary of the results obtained from the trial.
This joint research is the first step in finding a therapeutic agent together. Although this joint research period will be short and preliminary, we would like to conduct a long-term joint research not only to find new drugs to treat diseases in the long term, but also to determine what kind of lifestyles and existing medications can stabilize your conditions.
The contents of “Study of Specific Immune Conditions of Autoimmune Diseases” in the information website “RareS.” for Intractable disease and rare disease
Content of research and application: https://raresnet.com/special/pcrd2-pro01/
About PCRD² (https://3h-holdings.co.jp/20190517/)
This program supports the participation of patients to research and development in the area of rare diseases and intractable diseases and the promotion of research. Patients will provide testing samples and researchers will bear the costs necessary for providing information to patients within the range that does not affect intellectual property and the expenses for using the samples.
About Social Cooperation Program of IT Healthcare, Graduate School of Pharmaceutical Sciences, The University of Tokyo (https://plaza.umin.ac.jp/ithc-utokyo/)
The course is conducted by six joint research companies, including the Graduate School of Pharmaceutical Sciences, The University of Tokyo and 3H Holdings Inc. to conduct research on drug development and innovation of proper use through ICT utilization. The main researches are as follows:
- Construction of regulatory science of data reliability necessary for conducting home and remote clinical trials
- Programming of ICT education required by pharmacists, systematization of medication information, and establishment of a system to support pharmacies
- Programing of education on drug development and data utilization for leadership development to promote patient group activities
- Realization of disease epidemiology and medical innovation by exploratory analysis of Real World Data
Organization Overview
KOTAI Biotechnology, Inc.
Location: 2F, Bldg. B of Office for Industry-University Co-Creation, Osaka University, 2-1 Yamadaoka, Suita, Osaka
Representative: Kazuo Yamashita, CEO
Website: https://www.kotai-bio.com/
3H Holdings Inc.
Location of headquarters: Ikebukuro YS building 2F, 1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo
Presentative: Sho Ando, CEO
Nature of business: Group Business Administration, Research on Life Science
Company website: https://3h-holdings.co.jp
Inquiries from patients
Information website “RareS.” for Intractable disease and rare disease
Mail：info@raresnet.com
Opening hours: 10:00-18:00 (except Saturdays, Sundays and public holidays)